Introduction {#Sec1}
============

Psoriasis is a major inflammatory disease with significant associated comorbidities, including cardiovascular disease, inflammatory bowel disease, metabolic syndrome, and psoriatic arthritis \[[@CR1]\]. Health-related quality of life (HRQoL) is increasingly recognized as an important element of the overall clinical assessment of psoriasis rather than simply an adjunct to objective measures of disease \[[@CR2]\]. The Dermatology Life Quality Index (DLQI) is a short, self-administered, dermatology-specific questionnaire that is the most commonly used tool to evaluate HRQoL in psoriasis clinical research \[[@CR2], [@CR3]\]. Objective clinical manifestations of psoriasis are commonly assessed with the Psoriasis Area and Severity Index (PASI), a validated scale that has been demonstrated to quantify clinical improvement in response to treatment \[[@CR4], [@CR5]\].

Although it is difficult to correlate absolute values of the PASI and DLQI, several studies have explored the relationship between reductions in the objective severity of psoriasis as measured with the PASI and improvements in HRQoL as measured with the DLQI \[[@CR6]\]. In secondary analyses of 1,469 patients with moderate-to-severe plaque psoriasis from two clinical trials of the tumor necrosis factor (TNF) inhibitor adalimumab, a 90% or greater improvement in the PASI (PASI 90 response) was associated with a greater improvement in the DLQI than that associated with a 75% or greater improvement in the PASI (PASI 75 response) \[[@CR7]\]. Further, a study of the TNF inhibitor infliximab for severe plaque psoriasis demonstrated that the percent change in the PASI and the percent change in the DLQI for the combined infliximab and placebo groups were strongly correlated (Spearman's correlation of 0.61) \[[@CR8]\]. Additionally, patients who achieved a PASI 75 response had a greater mean improvement in the DLQI (81%) compared with patients who achieved 50--75% improvement in the PASI (60% improvement in the DLQI). Katugampola et al. \[[@CR9]\] examined associations between the PASI and the DLQI in multiple clinical trials of four biologics (etanercept, infliximab, efalizumab, and alefacept) and reported that improvement in the DLQI paralleled improvement in the PASI 75 with treatment. Conversely, patients who had responded to ustekinumab treatment (PASI 75 responders) and were re-randomized to placebo during a withdrawal period exhibited rapid worsening of DLQI scores in parallel with loss of the PASI response; however, the association between DLQI and PASI scores was not formally analyzed \[[@CR10]\]. To date, no studies have compared the correlation between PASI and DLQI scores during effective disease control and after withdrawal of therapy.

In a double-blind, randomized, controlled phase 3 trial (Randomized Controlled EValuation of Adalimumab Every Other Week Dosing in Moderate to Severe Psoriasis TriAL \[REVEAL\]; Clinicaltrials.gov \#NCT00237887), patients who underwent a protocol-mandated discontinuation of treatment at week 33 experienced a loss of adequate response \[defined as a \<50% reduction in PASI score relative to baseline (week 0) and a ≥6-point increase in the PASI score compared with week 33\] at a significantly higher rate than patients who were randomized to continue active treatment (28% vs. 5%; *P* \< 0.001) \[[@CR11]\]. We hypothesized that patients who had achieved a clinical response in REVEAL and whose treatment was then discontinued would experience a worsening of dermatology-specific HRQoL out of proportion to the worsening of the objective signs of disease.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

This was a post hoc analysis of a phase 3, multicenter, 52-week, double-blind, placebo-controlled trial (REVEAL) performed at 81 sites across the USA and Canada (Clinicaltrials.gov \#NCT00237887) \[[@CR11]\]. The protocol was approved by the institutional review board of each participating medical center. The REVEAL study consisted of three treatment periods (Fig. [1](#Fig1){ref-type="fig"}). In period A (weeks 0--16), patients were randomized 2:1 using an interactive voice response system to receive double-blind subcutaneous injections of adalimumab or placebo. An initial dose of adalimumab (80 mg) or placebo was administered at week 0, followed by 40 mg adalimumab or placebo every other week (eow) from weeks 1 to 15. Patients who achieved PASI 75 at week 16 were eligible to enter the open-label period (period B, weeks 16--33). To maintain blinding at week 16, patients who had received placebo during period A received two injections of adalimumab (40 mg), while patients who had received adalimumab were given two injections of placebo. All patients received adalimumab (40 mg eow) from weeks 17 to 31. Patients who achieved PASI 75 responses at week 33 were eligible to enter period C (weeks 33--52). Patients originally randomized to adalimumab in period A were then re-randomized 1:1 to receive double-blind adalimumab or placebo from weeks 33 to 52 (period C). Patients who received placebo in period C are the focus of this analysis.Fig. 1REVEAL study design. Patients originally randomized to adalimumab in period A (weeks 0--16) who achieved PASI 75 responses at week 16 (after double-blind treatment) and week 33 \[after open-label period B (weeks 16--33)\] were then re-randomized to double-blind adalimumab or placebo in period C (weeks 33--52). This analysis examined the cohort of 240 patients treated with placebo in period C. \*40 mg eow from week 1 after 80 mg at week 0; ^†^40 mg eow from week 17 after 80 mg at week 16. Adapted with permission from Menter et al. \[[@CR11]\]. *DBPC* double-bind, placebo controlled, *eow* every other week, *OLE* open-label extension, *PASI* Psoriasis Area and Severity Index, *REVEAL* Randomized Controlled EValuation of Adalimumab Every Other Week Dosing in Moderate to Severe Psoriasis TriAL

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study.

Patients {#Sec4}
--------

Males and females aged 18 years or older with a clinical diagnosis of moderate-to-severe plaque psoriasis (affected body surface area ≥10%) for at least 6 months were eligible for the REVEAL study \[[@CR11]\]. PASI scores of 12 or greater and Physician's Global Assessment of at least "moderate" were required for eligibility. Key exclusion criteria included previous exposure to any systemic anti-TNF therapy and the inability to discontinue phototherapy or topical or systemic therapies. All patients provided written informed consent.

Efficacy Assessments {#Sec5}
--------------------

The DLQI consists of four components: symptoms and feelings (DLQIS); daily activities (DLQID); leisure (DLQIL); and personal relationships (DLQIP). DLQI total scores may range from 0 to 30, with a higher score indicating poorer HRQoL. A DLQI total score of more than 5 indicates a moderate effect of psoriasis on patient HRQoL; a DLQI score of more than 10 indicates a very large effect; and a DLQI score of more than 20 indicates an extremely large effect \[[@CR12]\]. Thus, a DLQI total score of more than 10 supports the need for a more aggressive intervention. PASI scores may range from 0 to 72, with higher scores indicating greater disease severity. Post hoc comparisons of DLQI and PASI scores were evaluated at baseline, early in treatment (week 4), at the last point when all patients had at least a PASI 75 response (week 33), and after randomized treatment discontinuation (up to 19 weeks after discontinuation).

Statistical Analysis {#Sec6}
--------------------

Patients who received adalimumab during period A, achieved PASI 75 responses at week 16 and week 33, and were subsequently re-randomized to placebo during period C were the focus of this subanalysis. Missing data were imputed using the last observation carried forward. The correlation between DLQI component or total score and PASI score at weeks 4 and 52 was analyzed by linear regression using SAS version 9.1 (SAS Institute Inc., Cary, NC, USA). No other statistical hypothesis testing was conducted for this post hoc analysis.

Results {#Sec7}
=======

Patients {#Sec8}
--------

Demographic and baseline disease activity characteristics of patients (*N* = 240) in the subanalysis population (Table [1](#Tab1){ref-type="table"}) appeared generally similar to those of patients in the overall study population \[[@CR11]\]. The mean age of patients was approximately 43 years; most patients were male and nearly all were white. Baseline disease characteristics were consistent with moderate-to-severe psoriasis; the mean DLQI score at baseline (11.6) was \>10, suggesting that, on average, psoriasis had a very large effect on HRQoL.Table 1Demographics and baseline clinical characteristics of patients re-randomized to placebo during period CDouble-blind period C (*N* = 240)Age (mean ± SD), years43.4 ± 13.2Male, *n* (%)179 (74.6)White, *n* (%)222 (92.5)Weight (mean ± SD), kg88.5 ± 19.2PASI score (mean ± SD)19.5 ± 7.8BSA (mean ± SD), %27.0 ± 16.8VAS for plaque psoriasis and psoriatic arthritis (mean ± SD)38.6 ± 30.0^a^Psoriasis-related pruritus assessment (mean ± SD)7.1 ± 2.3^a^DLQI score (mean ± SD)11.6 ± 6.8Patients originally randomized to adalimumab in period A (weeks 0--16) who achieved PASI 75 responses at week 16 (after double-blind treatment) and week 33 \[after open-label period B (weeks 16--33)\] were then re-randomized to double-blind adalimumab or placebo in period C (weeks 33--52)*BSA* body surface area affected by psoriasis, *DLQI* Dermatology Life Quality Index, *PASI* Psoriasis Area and Severity Index, *VAS* visual analog scale^a^ *n* = 237

PASI Response {#Sec9}
-------------

The proportion of patients with PASI 75, PASI 90, or PASI 100 responses decreased after discontinuation of therapy (Fig. [2](#Fig2){ref-type="fig"}). All patients had PASI 75 responses at week 33, but most of these patients lost PASI 75 response at week 52, following discontinuation of treatment. Similarly, the proportion of patients achieving a PASI 90 response decreased from 71.7% at week 33 to 20.3% at week 52, and the PASI 100 response rate decreased from 37.9% at week 33 to 8.4% at week 52. Thus, discontinuation of therapy at week 33 resulted in recurrence of psoriasis symptoms by week 52.Fig. 2Proportion of patients achieving PASI 75, PASI 90, and PASI 100 responses over time in the ITT population (LOCF). Patients who achieved PASI 75 responses with adalimumab at week 33 and then discontinued treatment (received placebo) until week 52 are presented. For week 52, only patients who had at least 1 post-week 33 assessment were included in the LOCF analysis. *ITT* intent to treat, *LOCF* last observation carried forward, *PASI* Psoriasis Area and Severity Index

PASI vs. DLQI {#Sec10}
-------------

Mean PASI and DLQI scores at baseline, week 4, week 33, and week 52 are reported in Fig. [3](#Fig3){ref-type="fig"}. Mean PASI scores decreased from baseline to week 4 and continued to decline until week 33, indicating improvement in psoriasis symptoms. Mean PASI score increased from week 33 to week 52, indicating recurrence of disease symptoms upon discontinuation of treatment. Mean DLQI scores followed a similar pattern. However, although the mean PASI score at week 52 (6.7) remained lower than the PASI score at week 4 (8.0), the mean DLQI score at week 52 (5.3) was higher than at week 4 (4.3). Therefore, at the end of the study, PASI scores remained lower (indicating an improvement) compared with early treatment, whereas the mean DLQI score was worse at the end of the study compared with a time point early in treatment, suggesting a disproportionate worsening of HRQoL relative to the severity of psoriasis.Fig. 3Mean PASI (**a**) and DLQI (**b**) scores in the ITT population (LOCF). Adalimumab was discontinued at week 33. PASI scale: 0--72. DLQI scale: 0--30. *DLQI* Dermatology Life Quality Index, *ITT* intent to treat, *LOCF* last observation carried forward, *PASI* Psoriasis Area and Severity Index

To examine the association between the PASI and DLQI, the correlation between PASI scores and DLQI scores was evaluated by linear regression early in treatment (week 4) and 19 weeks after discontinuation of therapy (week 52). For every unit increase in PASI score, there was a disproportionately larger increase (i.e., worsening) in DLQI total score at week 52 compared with week 4 (Fig. [4](#Fig4){ref-type="fig"}). The slope of the regression line for DLQI versus PASI was 0.5094 at week 52 and 0.1978 at week 4, indicating that each unit change in PASI was associated with approximately twice as much change in DLQI at week 52 compared with the change at week 4. Linear regression modeling showed a significant interaction (*P* \< 0.0001) between study period (week 4 or week 52) and the relationship of PASI to DLQI, indicating that the correlation between PASI and DLQI was different early in treatment (week 4) from the correlation 19 weeks after discontinuation of treatment (week 52). The disproportionate worsening in DLQI scores was less apparent for patients with PASI 75 responses. Patients who experienced substantial worsening of disease (e.g., \<PASI 50) had the largest difference in DLQI scores between week 4 and week 52 (Fig. [5](#Fig5){ref-type="fig"}). Changes in these patients made the largest contribution to the mean worsening of DLQI scores. Correlations of individual DLQI component scores with PASI also differed before and after discontinuation of therapy. The slope of the regression line for DLQID versus PASI was 0.0413 at week 4 and 0.1153 at week 52; DLQIL versus PASI was 0.0384 at week 4 and 0.0849 at week 52; DLQIP versus PASI was 0.0281 at week 4 and 0.0578 at week 52; and DLQIS versus PASI was 0.0644 at week 4 and 0.1704 at week 52. Thus, the correlations of DLQIS and DLQID with PASI exhibited the most striking differences between a time point early in treatment and after discontinuation.Fig. 4Scatter plot for week 4 and week 52 DLQI vs. PASI (LOCF; ITT population). *DLQI* Dermatology Life Quality Index, *ITT* intent to treat, *LOCF* last observation carried forward, *PASI* Psoriasis Area and Severity IndexFig. 5Mean DLQI score by PASI response categories. *DLQI* Dermatology Life Quality Index, *PASI* Psoriasis Area and Severity Index

Discussion {#Sec11}
==========

Within 19 weeks after therapy was discontinued per protocol in patients who had responded well to treatment, PASI and DLQI scores showed recurrence of psoriasis symptoms and increased impairment of HRQoL. A post hoc analysis demonstrated that DLQI total scores worsened disproportionately relative to PASI scores, a difference that reached statistical significance; thus, HRQoL worsened disproportionately relative to the objective signs of disease recurrence. The patterns of correlations of DLQI component scores with PASI scores before and after treatment discontinuation supported the results obtained for the DLQI total score. Although the reason for the asymmetry between PASI and DLQI cannot be determined from the results of this analysis, we hypothesize that it occurred because patients were distressed by the recurrence of psoriasis symptoms that had been effectively controlled. Even mild disease recurrence may have had a negative effect on DLQI scores, perhaps because patients recalled the previous deleterious effects of more severe disease activity on their HRQoL. The psychological impact of psoriasis on patients is well documented. Patients with psoriasis have higher levels of anxiety and depression than healthy controls and often experience emotions of shame, worry, anger, and annoyance \[[@CR13]--[@CR15]\]. Recently, Ghajarzadeh et al. \[[@CR16]\] reported significant correlations between DLQI scores and Beck Depression Inventory (BDI) scores in patients with psoriasis. Patients with psoriasis had BDI scores indicative of mild-to-moderate depression and DLQI scores demonstrating impaired HRQoL.

The results of this exploratory analysis of randomized withdrawal of adalimumab are consistent with a substantial link between treatment response and patient HRQoL; we hypothesize that findings would be similar with discontinuation of other treatments. The results of the current study highlight the importance of continuous therapy in patients with psoriasis. Even temporary discontinuations of treatment may be inadvisable in patients who have achieved disease control. Conversely, in the authors' clinical experience, the erosion of HRQoL after treatment interruption may be a primary factor in influencing patients to reinitiate therapy. In support of these considerations, a recent systematic review concluded that continuous therapy is preferred for maintenance of disease control and HRQoL \[[@CR17]\].

This study benefited from a double-blind design that may have minimized bias by masking assignment to continue adalimumab or receive placebo; this was probably particularly important for a subjective, patient-reported outcome such as the DLQI. Additional strengths were that the study was conducted at a large number of centers and that many patients were analyzed. Limitations of the study are that it was a post hoc analysis and, therefore, potentially subject to bias. Additionally, the comparison of PASI and DLQI scores was not evaluated beyond the relatively short period of 19 weeks after discontinuation of treatment. Finally, inherent limitations of the DLQI and PASI have been reported. Problems with the DLQI include inadequate measurement of mild illness, interpretability that has been rated only "acceptable," and differential item functioning by disease, age, and sex \[[@CR3], [@CR18]\]. Although the PASI is the most thoroughly validated scale for psoriasis and is used extensively in clinical trials \[[@CR4]\], it has been criticized for having a nonlinear scale, poor sensitivity, and lack of standardization for translation into corresponding clinical severity categories \[[@CR19]\]. PASI scores on the lower end of the range (PASI \<10) are less meaningful, so comparisons with DLQI scores among patients with low PASI scores may be more difficult. Furthermore, consistency and reliability of the PASI are influenced by the experience level of the physician \[[@CR20]\]. Due to these limitations, this analysis must be considered exploratory and hypothesis generating; a prospective study would be needed to confirm the findings.

Conclusion {#Sec12}
==========

Discontinuing therapy, as observed in this analysis with adalimumab, has several negative effects in patients with psoriasis, including a loss of objective response and a disproportionately large negative impact on HRQoL. Interruption of treatment will likely result in an increase of psoriasis symptoms and a disproportionate decrease in HRQoL.
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